Company intelligence / Profile preview

Suzhou Junde Biotechnology Co., Ltd.

Suzhou, Jiangsu Sheng, Chinateligenebio.cn ↗

Ownership: Private
Development stage: Phase 2

Overview

The company's lead drug TL117 (PI3K inhibitor) is in Phase 2 clinical trials for Recurrent Squamous Cell Carcinoma of the Head and Neck. A clinical trial (CTR20210491) is currently recruiting patients to evaluate TL117 capsule as a monotherapy and in combination with paclitaxel for recurrent/metastatic cancer[1][9].

Therapeutic areas: Oncology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

TL117

Beyond the preview

Go deeper on Suzhou Junde Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Junde Biotechnology Co., Ltd..

Explore the full profile